AGENT™
Drug-Coated Balloon
The AGENT IDE Clinical Trial showed that AGENT DCB is superior to conventional balloon angioplasty in reducing target lesion failure for the treatment of coronary in-stent restenosis (ISR).1
AGENT IDE Clinical Trial
![AGENT IDE Study Design](https://www.bostonscientific.com/en-EU/products/balloons--drug-coated/agent/agent-ide-trial/_jcr_content/maincontent-par/image_917730807.img.IDE%20Study%20Design-v4.jpg)
Primary Endpoint²
![Primary Endpoint](https://www.bostonscientific.com/en-EU/products/balloons--drug-coated/agent/agent-ide-trial/_jcr_content/maincontent-par/image_1309411445.img.primary-endpoint-final.jpg)
![The TLF relative risk reduction from using AGENT DCB was approximately 38%.](https://www.bostonscientific.com/en-EU/products/balloons--drug-coated/agent/agent-ide-trial/_jcr_content/maincontent-par/image_132585547.img.blurb1-v2.jpg)
Additional Endpoints²
At 1-year, AGENT DCB also demonstrated statistically lower event rates:
- 51% risk reduction in TLR (12.4% vs. 24.0%, P=0.002)
- 49% risk reduction in TV-MI (6.4% vs 12.3%, P=0.03)
- Zero definite/probable ST (0.0% vs. 3.9%, P=0.001)